Patents by Inventor Beibei Chen
Beibei Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200405715Abstract: The present disclosure is directed to, e.g., 3-substituted, 5-amine-substituted-cyclohex-2-en-1-one compounds, and method of treatment and making associated with the same compounds.Type: ApplicationFiled: February 24, 2017Publication date: December 31, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Beibei Chen, Yuan Liu
-
Patent number: 10869866Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: GrantFiled: June 18, 2019Date of Patent: December 22, 2020Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Publication number: 20200216426Abstract: A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy; R8 is an optionally-substituted heterocycloalkyl; and a is 0 to 3.Type: ApplicationFiled: June 25, 2018Publication date: July 9, 2020Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, Yuan Liu
-
Publication number: 20200113900Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: ApplicationFiled: June 18, 2019Publication date: April 16, 2020Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Publication number: 20200087294Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.Type: ApplicationFiled: October 11, 2019Publication date: March 19, 2020Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Publication number: 20200062693Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.Type: ApplicationFiled: October 4, 2017Publication date: February 27, 2020Inventors: Beibei CHEN, Rama K. MALLAMPALLI, Yuan LIU
-
Publication number: 20190367462Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.Type: ApplicationFiled: June 7, 2019Publication date: December 5, 2019Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: Beibei CHEN
-
Patent number: 10487076Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.Type: GrantFiled: December 10, 2015Date of Patent: November 26, 2019Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government, as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Patent number: 10369150Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: GrantFiled: October 10, 2018Date of Patent: August 6, 2019Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Patent number: 10344003Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.Type: GrantFiled: April 21, 2016Date of Patent: July 9, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Beibei Chen
-
Patent number: 10307423Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: GrantFiled: April 25, 2016Date of Patent: June 4, 2019Assignees: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Publication number: 20190091222Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: ApplicationFiled: October 10, 2018Publication date: March 28, 2019Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Patent number: 10159674Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.Type: GrantFiled: April 25, 2016Date of Patent: December 25, 2018Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Patent number: 10092526Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, C3-7heterocycloalkyl, C3-7heterocycloalkyl-C1-6alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.Type: GrantFiled: November 17, 2017Date of Patent: October 9, 2018Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama Mallampalli
-
Publication number: 20180141916Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.Type: ApplicationFiled: April 21, 2016Publication date: May 24, 2018Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: Beibei CHEN
-
Publication number: 20180134693Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.Type: ApplicationFiled: December 10, 2015Publication date: May 17, 2018Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama K. Mallampalli
-
Publication number: 20180071232Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, C3-7heterocycloalkyl, C3-7heterocycloalkyl-C1-6alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.Type: ApplicationFiled: November 17, 2017Publication date: March 15, 2018Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama Mallampalli
-
Patent number: 9849098Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.Type: GrantFiled: December 9, 2014Date of Patent: December 26, 2017Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama Mallampalli
-
Patent number: 9765573Abstract: A composite tungsten carbide insert (B, I) with heterogeneous composition and structure has a working part (W) and a non-working part (N). The working part (W) is made of a tungsten carbide material consisting of tungsten carbide powder and cobalt powder or nickel. The non-working part (N) is made of a low density tungsten carbide material consisting of titanium carbide powder, tungsten carbide powder, and cobalt powder or nickel powder. During pressing, the tungsten carbide material for the working part (W) and the low density tungsten carbide material for the non-working part (N) are weighed and added to a steel die successively for molding and then sintering. The non-working part (N) which accounts for most of the overall product volume has low density and less material consumption, and can greatly reduce the raw material costs of the product, significantly improving the performance-cost ratio of the insert (B, I).Type: GrantFiled: September 30, 2016Date of Patent: September 19, 2017Assignee: Shanghai Gogoal Industry Co., Ltd.Inventors: Dacheng Luo, Shun Lin, Beibei Chen
-
Publication number: 20170014912Abstract: A composite tungsten carbide insert (B, I) with heterogeneous composition and structure has a working part (W) and a non-working part (N). The working part (W) is made of a tungsten carbide material consisting of tungsten carbide powder and cobalt powder or nickel. The non-working part (N) is made of a low density tungsten carbide material consisting of titanium carbide powder, tungsten carbide powder, and cobalt powder or nickel powder. During pressing, the tungsten carbide material for the working part (W) and the low density tungsten carbide material for the non-working part (N) are weighed and added to a steel die successively for molding and then sintering. The non-working part (N) which accounts for most of the overall product volume has low density and less material consumption, and can greatly reduce the raw material costs of the product, significantly improving the performance-cost ratio of the insert (B, I).Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Applicant: Shanghai Gogoal Industry Co., LtdInventors: Dacheng Luo, Shun Lin, Beibei Chen